β-Ecdysterone Enhanced Bone Regeneration Through the BMP-2/SMAD/RUNX2/Osterix Signaling Pathway

Cai-Ping Yan1,2†, Xing-Kuan Wang1,2†, Ke Jiang1,2*, Chong Yin3, Chao Xiang1,2, Yong Wang1,2, Chaoyu Pu1,2, Lu Chen1 and Yu-Ling Li1,2*

1Department of Orthopaedics, Affiliated Hospital of North Sichuan Medical College, Nanchong, China, 2Laboratory of Biological Tissue Engineering and Digital Medicine, Affiliated Hospital of North Sichuan Medical College, Nanchong, China, 3Laboratory for Bone Metabolism, Xi’an Key Laboratory of Special Medicine and Health Engineering, Key Lab for Space Biosciences and Biotechnology, NPU-UAB Joint Laboratory for Bone Metabolism, Research Center for Special Medicine and Health Systems Engineering, School of Life Sciences, Northwestern Polytechnical University, Xi’an, China

Bone defects are a global public health problem. However, the available methods for inducing bone regeneration are limited. The application of traditional Chinese herbs for bone regeneration has gained popularity in recent years. β-ecdysterone is a plant sterol similar to estrogen, that promotes protein synthesis in cells; however, its function in bone regeneration remains unclear. In this study, we investigated the function of β-ecdysterone on osteoblast differentiation and bone regeneration in vitro and in vivo. MC3T3-E1 cells were used to test the function of β-ecdysterone on osteoblast differentiation and bone regeneration in vitro. The results of the Cell Counting Kit-8 assay suggested that the proliferation of MC3T3-E1 cells was promoted by β-ecdysterone. Furthermore, β-ecdysterone influenced the expression of osteogenesis-related genes, and the bone regeneration capacity of MC3T3-E1 cells was detected by polymerase chain reaction, the alkaline phosphatase (ALP) test, and the alizarin red test. β-ecdysterone could upregulate the expression of osteoblastic-related genes, and promoted ALP activity and the formation of calcium nodules. We also determined that β-ecdysterone increased the mRNA and protein levels of components of the BMP-2/Smad/Runx2/Osterix pathway. DNA sequencing further confirmed these target effects. β-ecdysterone promoted bone formation by enhancing gene expression of the BMP-2/Smad/Runx2/Osterix signaling pathway and by enrichment biological processes. For in vivo experiments, a femoral condyle defect model was constructed by drilling a bone defect measuring 3 mm in diameter and 4 mm in depth in the femoral condyle of 8-week-old Sprague Dawley male rats. This model was used to further assess the bone regenerative functions of β-ecdysterone. The results of micro-computed tomography showed that β-ecdysterone could accelerate bone regeneration, exhibiting higher bone volume, bone surface, and bone mineral density at each observation time point. Immunohistochemistry confirmed that the β-ecdysterone also increased the expression of collagen, osteocalcin, and bone morphogenetic protein-2 in the experiment group at 4 and 8 weeks. In conclusion, β-ecdysterone is a new bone regeneration regulator that can...
stimulate MC3T3-E1 cell proliferation and induce bone regeneration through the BMP-2/Smad/Runx2/Osterix pathway. This newly discovered function of β-ecdysterone has revealed a new direction of osteogenic differentiation and has provided novel therapeutic strategies for treating bone defects.

**Keywords:** β-ecdysterone, bone regeneration, bone morphogenetic protein-2 (BMP2), RUNX 2, Smad

---

**INTRODUCTION**

Bone defect refers to the destruction of the structural integrity of the phalanx, and complete or partial destruction of its continuity. Studies have shown that a variety of signal transduction mechanisms regulate bone growth metabolism and regeneration after bone injury. When these critical signal transduction mechanisms that promote bone growth are not fully activated or destroyed, bone formation is reduced and bone marrow fat accumulation increases, resulting in impaired bone regeneration (Hak et al., 2014; Yu et al., 2018). Bone regeneration is a highly complex but organized process that requires damaged bones to return to their pre-injury cellular structure and biomechanical functions (Schindeler et al., 2008). Both, intramembranous and endochondral ossification are essential forms of bone regeneration (Phillips 2005; Takigawa 2013; Ko and Sumner 2021). In the process of intramembranous ossification, bone marrow mesenchymal stem cells (BMSCs) differentiate directly into osteoblasts and deposit mineralized extracellular matrix to achieve bone regeneration (Percival and Richtsmeier 2013). BMSCs are cells with multi-differentiation potential, and have the ability to differentiate into bone, cartilage, fat, nerves, or myoblasts *in vivo* and *in vitro* (Sumer, Liu et al., 2018, Yang et al., 2019; Zhao et al., 2020). BMSCs can also secrete a variety of cytokines (such as BMP-2, IGF-1, IL-6, and M-CSF) to promote bone regeneration (Meirelles et al., 2009). On exposure to certain specific chemical mediators, cytokines, and mechanical stimulation, intracellular BMP-Smad, Wnt/β-catenin, Notch, Hedgehog, or other signaling pathways of BMSCs are activated to promote osteoblast differentiation (Abdallah et al., 2005). However, when the specific environment is destroyed due to various diseases, BMSCs show abnormal osteogenic differentiation, an imbalance of metabolic regulation, which reduces the bone remodeling rate, bone matrix, and bone mineral deficiency; eventually, this can cause bone regeneration deficiency, osteoporosis, and osteomalacia (Liu et al., 2018). It is therefore essential that strategies are identified to effectively regulate the function of BMSCs for promoting osteogenic differentiation and bone regeneration.

In recent years, researchers have tried various approaches to boost stem cell function. Basic and clinical studies are increasingly investigating the promotion of osteogenic differentiation of BMSCs and the mechanisms involved, including traditional cytokines and related physical and...
chemical stimulation factors. Osteoblast growth peptide promotes osteogenic differentiation of BMSCs through the RhoA/ROCK pathway in a dose-dependent manner (Chen et al., 2011). Boron can promote the synthesis of osteogenic genes in the proliferation and differentiation of human BMSCs (Ying et al., 2011). The BMP-2 related peptides P24 (Lin et al., 2010) and simvastatin (Feng et al., 2020) also promote osteogenic differentiation and proliferation of BMSCs. BMPs are acidic proteins located in the bone matrix, and belong to the TGF-β superfamily. BMPs serve essential roles in skeletal development, bone formation, and MSC differentiation (Cai et al., 2021). Research has shown that fenofibrates induce PPARα and BMP2 expression to stimulate osteoblast differentiation; however, disruption in BMP signaling causes skeletal and vascular abnormalities (Miyazono, Kamiya and Morikawa 2010). In this context, a study showed BMP-2 and BMP-4 knockouts to be embryonically lethal in mice (Scarfì 2016). Thus, BMP2 serves an important role in inducing the osteogenic differentiation of MSCs (Toth et al., 2021).

In their study, Jian et al. (2013) applied 50, 100, and 200 μmol/ L β-ecdysterone to human periodontal membrane stem cells (PDLSs) in vitro and confirmed that 200 μmol/L β-ecdysterone could effectively induce BMP-2 expression and osteogenic differentiation of periodontal membrane stem cells through the extracellular signal-regulated kinase pathway (Jian et al., 2013). However, it is unclear whether these positive effects of β-ecdysterone can also affect BMSCs and the specific molecular mechanisms involved and whether they can be applied to bone regeneration in animals or clinics. β-ecdysterone is a polyhydroxylated steroid hormone, which is most abundant in insects and Anatable plants. It is known as a phytoestrogen, because its chemical structure is similar to that of estrogen (Zou et al., 2015). β ecdysterone can not only stimulate protein synthesis (Töth et al., 2008), promote carbohydrate and lipid metabolism (Catalán et al., 1985), control blood glucose level (Yoshida et al., 1971), inhibit cell apoptosis (Tang et al., 2018a), and improve intervertebral disc degeneration (Wen et al., 2019), but it also has good biocompatibility (Dai et al., 2017). Chinese herbal medicines such as Achyranthes bidentata have been used for centuries to treat osteoporosis and joint degeneration in China, and no side effects have been reported for hundreds of years. Studies have shown that β-ecdysterone can stimulate arthropod midgut stem cells (Smagghe et al., 2005) and induce osteogenic differentiation of mouse mesenchymal stem cells (Gao, Cai and Shi 2008). β-ecdysterone can regulate the proliferation and osteogenic differentiation of BMSCs by targeting estrogen receptors in vivo and plays an essential role in the process of bone regeneration (Abiramamudari et al., 2018). However, the specific signal transduction mechanism involved, the regulation mode of gene differential expression, and the optimal drug dose have not been discussed in depth. Therefore, a better understanding of the interactions and mechanisms between β-ecdysterone and BMSCs is expected to positively impact bone regeneration and formation.

This study aimed to explore whether β-ecdysterone can promote osteogenic differentiation and functionalization of BMSCs, enhancing their ability to promote in situ bone regeneration. Furthermore, it elucidated the potential signal transduction mechanism, differential regulation of gene expression, and appropriate dose of β-ecdysterone in promoting bone regeneration. During the in-vitro experiments, we treated MC3T3-E1 cells with β-ecdysterone to assess their biocompatibility and the osteogenesis-promoting effect. Cell Counting Kit-8 (CCK-8) was used to verify the excellent biocompatibility of β-ecdysterone. Immunohistochemical staining and quantitative polymerase chain reaction (q-PCR) were used to verify the excellent expression of alkaline phosphatase (ALP), collagen I, and other osteogenic proteins in MC3T3-E1 cells treated with β-ecdysterone. The alizarin red staining experiment further verified that the system could effectively form mineralized nodules from the extracellular matrix. Subsequently, MC3T3-E1 cells treated with different doses of β-ecdysterone were analyzed by gene sequencing and differential expression analysis of osteogenic-related genes. β-ecdysterone could effectively improve the replication and transcription of intracellular BMP-Smad signaling pathway genes in a dose-dependent manner. Finally, we added noggin, a BMP2 signaling pathway blocker, to explore any possible relationship between the BMP-2 signaling pathway, metabolism of BMSCs, and osteogenic differentiation after β-ecdysterone treatment; this was performed to evaluate the potential mechanism of enhanced bone regeneration. q-PCR and western blotting showed that β-ecdysterone significantly increased the expression of mRNA and proteins in the BMP2 signaling pathway, and this effect was inhibited by noggin, a BMP2 signaling pathway blocker. Furthermore, we established a rat model of femoral bone defect in vivo to evaluate the effect of β-ecdysterone on bone regeneration mediated by BMSCs. The animal experiments showed that at week 4 and 8 after surgery, rats injected intraperitoneally with 72 mg/kg of β-ecdysterone had a higher degree of gross bone tissue growth, bone mineral density, and degree of ossification in regenerated bone tissue at the site of the bone defect (as observed on immunohistochemical staining) than in the other groups. Overall, our data suggested that β-ecdysterone can mediate bone regeneration via the BMP2/Smad/Runx/Osterix signaling pathway. This study provides a new approach to the treatment of bone injury and degenerative diseases represented by bone defects and osteoporosis.

MATERIALS AND METHODS

Materials

MC3T3-E1 cells (subclone 14) were purchased from Procell (Wuhan, China), induction medium (Cyagen, Guangzhou, China), α-modified Eagle medium (α-MEM, containing 4.5 g/L D-glucose, 25 mM HEPES), fetal bovine serum, 0.25% trypsin-EDTA, penicillin/streptomycin, and phosphate buffer saline (PBS) were purchased from HyClone (Logan, UT, United States). Triton X-100, bovine serum albumin, and alizarin red S were purchased from Sangon Biotech (Shanghai, China). The RNeasy Mini Kit was purchased from Qiagen (Düsseldorf, Germany). The PrimeScript RT Master Mix and the TB Green Premix Ex Taq were purchased from Takara.
TABLE 1 | RT-qPCR primer sequences.

| Gene       | Primer sequences                      |
|------------|---------------------------------------|
| Bmp-2      | Forward: 5′-CACGAGAATGACATGCCC-3′     |
|            | Reverse: 5′-GCTTCCGAGCAGCAAATCTGCT-3′ |
| Runx2      | Forward: 5′-GCTTTTGGATGCTGATTCC-3′   |
|            | Reverse: 5′-TGAACTCGACAGCTGATT-3′    |
| Osterix    | Forward: 5′-GATGCGCTCTCTCTGCTT-3′    |
|            | Reverse: 5′-AATGGCCTTCCTCTCGAACC-3′  |
| Collagen I | Forward: 5′-AAGGCTCCTCCTGGAAGAGAT-3′ |
|            | Reverse: 5′-CAAGATCCAACCTCGCTT-3′    |
| GAPDH      | Forward: 5′-TCTATGACAATTGTTGATC-3′   |
|            | Reverse: 5′-TGTAAGGCAATTGTTGCA-3′    |

(All primers were designed by Genscript (Tokyo, Japan). The CCK-8, 4% paraformaldehyde, 10% cetylpyridinium chloride monohydrate, and β-ecdysterone were purchased from Solarbio (Beijing, China). The alkaline phosphatase assay kit and the goat anti-rabbit IgGDAB kit were purchased from Beyotime (Shanghai, China). Noxgin, DAPI, SuperScript II reverse transcriptase, the RevertAid First Strand cDNA Synthesis Kit, and were purchased from Invitrogen (Thermo Fisher, United States), and 10% sodium dodecyl sulfate-polyacrylamide gel, cell lysis buffer, polyvinylidene fluoride membrane, and goat anti-rabbit antibody were purchased from Boster (Wuhan, China). All primary antibodies (type I collagen, osteopontin, BMP-2, Smad1/5, P-Smad1/5, Runx2, and Osterix) were purchased from Abcam. The animal anesthetic used was isoflurane (Jiangsu, Beikang, China), lidocaine (xylocaine 2%, Hebei Tiancheng, China).

**Cell Culture**

MC3T3-E1 cells were cultured in α-MEM medium supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 100 g/ml streptomycin at 37°C in 5% CO2. The medium was replaced every 2–3 days. When cell fusion reached 80% (80% of the dish was covered by cells), 0.25% trypsin-EDTA was used for digestion, isolation, and passage culture. In our experiment, MC3T3-E1 of the third generation was used.

**Cell Proliferation**

The CCK-8 assay was used to detect the biocompatibility of β-ecdysterone in MC3T3-E1 cells. MC3T3-E1 cells were incubated with 5 × 10⁵ cells/well in 96-well plates, and 200 µl of α-MEM was added to each well. After incubation for 24 h, β-ecdysterone (Solarbio, Beijing, China) was added to 96-well plates at a final concentration of 0, 50, 100, 150, 200, and 250 µM. The cells were then incubated for 1–7 days. At each observation time point, cells were washed with PBS thrice; 10 µl CCK-8 solution and 100 µl fresh α-MEM medium were added to each well and then incubated at 37°C for 1 h. The absorbance was measured at 460 nm using a microplate reader (Thermo Fisher United States).

**Alkaline Phosphatase Activity**

ALP activity was measured using an ALP Assay Kit (Beyotime, Shanghai, China). MC3T3-E1 cells were cultured in 6-well plates at 2 × 10⁴ cells/well. When the degree of cell fusion exceeded 60% (60% of the dish was covered by cells), β-ecdysterone was added to the medium at final concentrations of 0, 100, 150, and 200 µM with induction medium. After 3 or 7 days of culture, the cells were washed with PBS and fixed with 4% paraformaldehyde for 15 min. Triton X-100 was used to rupture the cell membranes and cell proteins were extracted by centrifugation at 12,000/min. According to the manufacturer’s instructions for the ALP kit, extracts from the control, standard, and experimental groups were transferred to 96-well plates, at volumes of 4, 8, 16, 24, 32, and 40 µl, respectively. The protein concentration was normalized before transfer. Detection buffer and chromogenic substrate were added to achieve a total volume 100 µl, and the reaction system was incubated in darkness at 37°C for 10 min. A stop buffer was added to each well to stop the reaction and the absorbance at 405 nm was measured using a microplate reader.

**Alizarin Red S Staining**

To test the mineralization ability of MC3T3-E1 cells induced by β-ecdysterone, calcium nodules were detected by alizarin red S staining. MC3T3-E1 cells were incubated at a density of 1 × 10⁴ cells/cm² in a dish (φ = 30 mm) and incubated in a medium containing 150 µM of β-ecdysterone or induction medium. The medium and β-ecdysterone were replaced every 3 days. On day 21, the cells were washed with PBS and fixed with 4% paraformaldehyde for 30 min; they were then stained with a 1% alizarin red S solution for 20 min. Decolorization was performed with 10% cetylpyridinium chloride monohydrate for 20 min, and absorbance was measured at 595 nm for quantitative analysis.

**Immunocytochemical Staining and Immunofluorescence Staining**

To investigate the effect of osteogenic-related protein expression in MC3T3-E1 cells treated with β-ecdysterone, MC3T3-E1 cells were incubated with 1.5 × 10⁴ cells/well in 6-well plates and cultured in standard medium, medium containing 150 µM/L β-ecdysterone, and induction medium. After 14 days of culture, the cells were washed thrice with PBS and fixed in 4% paraformaldehyde solution at room temperature for 15 min. The cells were washed again with PBS and treated with 0.1% Triton X-100 for 15 min. The cells were then incubated in a 5% bovine serum albumin solution at 37°C for 1 h. After washing the cells thrice with PBS, either osteopontin antibody (1:200) or secondary antibody and hematoxylin were added; the cells were then incubated at 4°C overnight, followed by incubation with goat anti-rabbit IgG at room temperature for 30 min. The DAB horseradish peroxidase chromogenic kit was used to detect osteopontin expression in cells. The nuclei were then stained with hematoxylin for 3 min and osteopontin staining was observed under an inverted microscope (Leica Microsystems CMS, Wetzlar, Germany).

Immunofluorescence staining was used to detect type I collagen expression in cells treated with different concentrations of β-ecdysterone. MC3T3-E1 cells were incubated with 1 × 10⁴ cells/well in 6-well plates and cultured in a medium containing 0, 100, 150, and 200 µM/L of β-
ecdysterone; alternatively, they were cultured in induction medium. In addition, noggin (0.5 mg/ml) was added in the control group. After 10 days of induction culture, the cells were fixed at room temperature with 4% paraformaldehyde for 30 min, washed thrice with PBS, and treated with Triton X-100 for 15 min to rupture the cell membranes. The cells were washed again with PBS and blocked at room temperature with 10% normal goat serum for 1 h. The primary antibody of type I collagen was added followed by incubation overnight at 4°C; this was followed by an appropriate dose of fluorescent secondary

### TABLE 2 | Effects of β-ecdysterone on the proliferation of MC3T3-E1 cells (OD value, X ± SD).

| Culture (day) | 0  | 50  | 100 | 150 | 200 | 250 |
|--------------|----|-----|-----|-----|-----|-----|
| 1            | 1.00 ± 0.13 | 1.30 ± 0.03** | 1.29 ± 0.07** | 1.30 ± 0.06** | 1.23 ± 0.11* | 1.20 ± 0.01* |
| 2            | 1.08 ± 0.09 | 1.64 ± 0.05*** | 1.69 ± 0.03*** | 1.88 ± 0.08*** | 1.54 ± 0.04*** | 1.54 ± 0.02*** |
| 3            | 1.19 ± 0.06 | 2.04 ± 0.05*** | 2.26 ± 0.06*** | 2.45 ± 0.08*** | 2.20 ± 0.01*** | 2.08 ± 0.05*** |
| 4            | 1.00 ± 0.03 | 1.69 ± 0.24* | 2.18 ± 0.34*** | 2.30 ± 0.12*** | 2.16 ± 0.17*** | 2.01 ± 0.27*** |
| 5            | 1.06 ± 0.08 | 2.75 ± 0.09*** | 2.78 ± 0.21*** | 2.89 ± 0.07*** | 2.65 ± 0.11*** | 2.50 ± 0.12*** |
| 6            | 1.98 ± 0.03 | 2.89 ± 0.14*** | 2.96 ± 0.07*** | 2.94 ± 0.07*** | 2.77 ± 0.15*** | 2.82 ± 0.06*** |
| 7            | 1.72 ± 0.03 | 1.91 ± 0.05** | 2.20 ± 0.26** | 2.37 ± 0.09* | 2.06 ± 0.09* | 1.77 ± 0.14** |

Values are expressed as means X ± SD (n = 5). The control group (0 μM) was compared with each experimental group. *p < 0.05, **p < 0.01, ***p < 0.001, NS, no significance.
antibody at room temperature for 30 min. The cells were rewarshed thrice with PBS and stained with DAPI nuclear stain (0.1 mg/ml; Sigma-Aldrich, St. Louis, MO, United States) for 15 min. A confocal laser scanning microscope (Olympus, Tokyo, Japan) was used to observe the distribution of type I collagen and the fluorescence intensity of type I collagen in the cytoplasm was quantified by ImageJ software (Wayne Rasband, NIH, United States). The determination was repeated thrice in each group.

RNA Sequence Analysis and Gene Enrichment Analysis
To observe and compare gene expression in MC3T3-E1 cells treated with β-ecdysterone, we performed RNA sequencing of the samples. Third generation MC3T3-E1 cells were incubated in a petri dish measuring 10 cm in diameter in a standard medium containing 0, 100, 150, and 200 μM of β-ecdysterone for 5 and 10 days. When the number of cells reached $3 \times 10^5$ cells/well, the RNA was extracted by TRIzol (Qiagen) lysis ($\mu$M), which was compared with each experimental group. The determination was repeated thrice in each group.

Real-Time-qPCR
Real-time PCR (RT-qPCR) was performed to further verify the results of gene sequencing and the impact of the β-ecdysterone on bone regeneration. MC3T3-E1 cells were incubated in 6-well plates at a density of $5 \times 10^5$ cells/well. When the cell density exceeded 60% (60% of the dish was covered by cells), induction medium with 150 μM of β-ecdysterone was added in the experimental group, and noggin (0.5 mg/ml) was added in the control group. On days 7 and 10, total RNA was extracted from MC3T3-E1 cells using TRIzol reagent and cDNA was synthesized using the RevertAid First Strand cDNA Synthesis Kit. The cDNA concentration was normalized before transfer. The RT q-PCR was performed using FastStart Universal SYBR Green Master (Rox) (Roche, Germany). The BMP2, Runx2, Osterix, Col I, and GAPDH primer sequences are shown in Table 1. Relative gene expression was calculated using the $2^{-\Delta\Delta CT}$ method and all experiments were repeated thrice.

Protein Electrophoresis Analysis
MC3T3-E1 cells were incubated in 6-well plates at a density of $5 \times 10^5$ cells/well. Cells cultured in a medium containing different concentrations (0–200 μM) of β-ecdysterone and noggin (0.5 mg/ml) were included in the experimental and control groups, respectively. After 7 days of induction culture, proteins were extracted with cell lysis buffer; the protein concentration was determined by Bio-Rad protein assay. Proteins denatured in equal amounts from different samples were separated by electrophoresis on 10% polyacrylamide gel electrophoresis. After electrotransfer to a polyvinylidene fluoride membrane, the membrane was blocked with 5% non-fat milk, then incubated with primary antibody at 4°C overnight. The goat anti-rabbit antibody (Boster) was then incubated at room temperature for 2 h. The ChemiDoc XRS + chemiluminescence detection system (BIO-RAD) was used for observation and the strip strength was analyzed using ImageJ software. The primary antibodies used were BMP-2 (1:1,000, Abcam), Smad1/5 (1:1,000, Abcam), P-Smad1/5 (1:1,000, Abcam), Runx2 (1:1,000, Abcam), and Osterix (1:1,000, Abcam). All experiments were repeated thrice.

Rat Model of Bone Defects
The animal experiments were approved by the Research Ethics Committee of the Affiliated Hospital of the North Sichuan Medical College (2021–26). Fifteen male Sprague Dawley rats (6–8 weeks old, weighing approximately 200 g) were selected for the animal experiments. The rat model of bone defects (Yan et al., 2019; Li and Helms 2021) was constructed after anesthetizing with inhalational isoflurane (for animals); an anesthesia ventilator was used for maintenance. The anesthesia protocol was as follows: a mask, and the concentration of isoflurane in 30% oxygen (Schubert et al., 2012). During anesthesia induction, the inhalational concentration of isoflurane in 1.5%–3.0% was maintained. Once the four limbs of the rat were limp and no pain reflex was elicited, continuous anesthesia was initiated, oxygen inhalation was maintained via a mask, and the concentration of isoflurane was maintained at 1%–2.5%. Incisions were performed after subcutaneous infiltration of lidocaine for local anesthesia. After the operation, the rats were allowed to breathe air freely until they were fully awake.

The specific method of surgery was as follows: after skin preparation, the medial condyle of the femur was exposed and

| Time (days) | β-ecdysterone (μM) | X ± SD (OD value) | DEA/mg |
|------------|-------------------|------------------|--------|
| 3          | 0                 | 0.132 ± 0.01     | 48.73  |
|            | 100               | 0.287 ± 0.03     | 129.51 |
|            | 150               | 0.503 ± 0.03     | 241.37 |
|            | 200               | 0.429 ± 0.03     | 202.79 |
|            | IM                | 0.442 ± 0.02     | 211.26 |
| 7          | 0                 | 0.148 ± 0.01     | 56.5   |
|            | 100               | 0.314 ± 0.01     | 143.49 |
|            | 150               | 0.860 ± 0.08     | 426.23 |
|            | 200               | 0.759 ± 0.08     | 373.93 |
|            | IM                | 0.766 ± 0.03     | 378.12 |

Values are expressed as means X ± SD (n = 6). **p < 0.01, ***p < 0.001. The “#” stands for the control group (0 μM), which was compared with each experimental group. **p < 0.01, ***p < 0.001. The “*” stands for the IM group, which was compared with each experimental group. #p < 0.05, ##p < 0.01, ###p < 0.001. ALP, alkaline phosphatase activity; DEA, deethanolamine enzyme activity unit.
a bone defect measuring 3 mm in diameter and 4 mm in depth was created using a K wire of 3.0 mm in diameter with a slow-speed electric drill; the site was irrigated using ice-cold saline solution to avoid thermal necrosis. The operative region was then sutured layer by layer. The sham operation group (n = 5) only received anesthesia and skin surgery, with no damage to the femur condyle. Rats with bone defects (n = 10) were categorized into 2 groups to receive intraperitoneal injections of 0 mg/kg of PBS (n = 5) and 72 mg/kg of β-ecdysterone (n = 5), respectively, every 3 days. At 4 and 8 weeks after surgery, the mice were over-anesthetized to death. The femur was harvested and fixed with a 4% paraformaldehyde solution for inspection.

**In Vivo Toxicology Studies**

The animals were segregated into three groups. The group of animals administered 72 mg/kg of intraperitoneal β-ecdysterone for 4 weeks comprised the experimental group; the group administered PBS served as the control group. The untreated mice served as the sham group. After 4 weeks of treatment, the animals were sacrificed by over-anesthesia. The liver and kidney tissues of rats were sectioned and stained with hematoxylin and eosin to observe toxicities in vivo.

**Micro-Computed Tomography Analysis**

All samples collected from rat models with femoral condylar defects were fixed in 4% paraformaldehyde at room temperature for 24 h. Micro-computed tomography (CT) (u-ct80, SCANCO, Switzerland) was used to test the samples (Clark and Badea 2021). Three-dimensional reconstruction was performed using the processed images (Scanco® software) and the bone volume, trabecular thickness, and bone mineral density of each group were detected and analyzed.

**Immunohistochemical Analysis**

All femoral condyle samples were decalcified and embedded in paraffin after micro-CT analysis. A 5-μm-thick tissue section was analyzed at the bone defect site for histomorphological analysis and the detection of new site-specific proteins of bone tissue (including BMP2 and Runx2). The sections were then stained with hematoxylin and eosin for histochemistry. Images of the histological specimen were obtained using a microscope (Eclipse E800; Nikon, Japan).

**Statistical Analysis**

Statistical analysis was performed using SPSS 23.0 (IBM Corp., Armonk, NY, United States) and GraphPad Prism 9 (GraphPad Software, United States). The independent sample t-test was used to evaluate statistical differences between the two groups and one-way analysis of variance (ANOVA) was used for multiple data groups. Data have been presented as means ± standard deviation. p < 0.05 was considered statistically significant.
RESULTS

β-Ecdysterone Promoted the Proliferation of MC3T3-E1 Cells In Vitro
To understand the biocompatibility of β-ecdysterone on MC3T3-E1 cells, we treated MC3T3-E1 cells with different concentrations of β-ecdysterone (0, 50, 100, 150, 200, and 250 μM); the CCK-8 assay was used to detect its effect on cell proliferation. The results showed that β-ecdysterone did not significantly inhibit the proliferation of MC3T3-E1 cells at different concentrations, but showed different proliferative abilities (Table 2; Figure 1A). Cell proliferation activity gradually increased with an increase in drug concentrations from 0 to 150 μM; however, this activity did not continue to increase when drug concentrations increased from 150 to 250 μM. Therefore, we treated cells with β-ecdysterone concentrations of 100, 150, and 200 μM in subsequent experiments.

β-Ecdysterone Enhance Osteogenic Differentiation of MC3T3-E1 Cells In Vitro
ALP is an osteoblast marker secreted at the beginning of osteogenic differentiation. To explore the role of β-ecdysterone in promoting osteogenic differentiation of MC3T3-E1 cells, we examined ALP activity in MC3T3-E1 cells. The results showed that intracellular ALP activity increased after treatment with different concentrations of β-ecdysterone (0, 100, 150, and 200 μM) for 3 and 7 days and the effect was dose- and time-dependent. In addition, 150 μM β-ecdysterone induced the most significant increase in ALP activity, which was significantly higher on day 7 than on day 3 (Table 3; Figure 1B).

Osteopontin (OPN) is an osteogenic marker secreted by osteoblasts in the middle and late stages of osteogenic differentiation. Immunocytochemical staining was performed on MC3T3-E1 cells treated with β-ecdysterone (0 and 150 μM) to investigate whether it also promoted MC3T3-E1 cells in the middle and late stages of osteogenic differentiation. The results showed that the brownish-yellow granules in the cytoplasm of the experimental group were significantly higher than those of the control group. There was no significant difference between the 150 μM β-ecdysterone and IM groups (Figure 1C). However, the nucleus was observed in the cells of the antibody controls (OPN group) in our study; no OPN expression was observed in the cytoplasm (Supplementary Figure S1).

During osteogenesis, osteoblasts undergo proliferation and gradually differentiate into osteocytes. Calcium salts are deposited in bone cells before they form bone tissue. The cells then fuse, mineralize, and form mineralized nodules. In our study, alizarin red staining was used to compare cells cultured for 21 days to investigate the effect of β-ecdysterone on mineralized nodule formation in MC3T3-E1 cells at the end stage of differentiation. The results showed that MC3T3-E1 cells cultured in osteoblast induction medium under β-ecdysterone intervention had more mineralized nodules than those cultured in osteoblast induction medium alone (Figure 1D). These results suggest that β-ecdysterone can enhance osteogenic differentiation of MC3T3-E1 cells and improve their ability to form bone tissue in vitro.

Gene Sequencing Analysis of MC3T3-E1 Cells Treated With β-Ecdysterone
To understand the specific effects of β-ecdysterone on nucleic acid transcription and expression in MC3T3-E1 cells, we used mRNA-seq to study the gene expression of MC3T3-E1 cells treated with β-ecdysterone at days 5 and 10. As shown in Figure 2A, among all detected mRNAs, 29,583 genes were found to be involved in gene expression analysis compared to the known mouse genome. In the experimental group, 1403 and 748 genes were up- and down-regulated, respectively; log2 > 1 and Q < 0.05 were established as indicators of significant difference. Further analysis of biological processes enriched by these differentially expressed genes using Kyoto Encyclopedia of Genes and Genomes clustering analysis and Gene Ontology functional enrichment analysis showed that genes of the BMP signaling pathway were among the top 20 upregulated genes; the differences were significant (Figures 2B,C). We analyzed the intersection of gene expression in MC3T3-E1 cells treated with β-ecdysterone for 5 and 10 days using Venn diagrams. A total of 1310 genes were up- or downregulated, including 859 upregulated genes (Figure 2D). We analyzed these 859 upregulated genes (Figure 2F) and found that osteogenesis-related genes (BMP and Wnt) were almost all upregulated; related signal transduction genes, including those associated with DNA integration and cell membrane receptors, were significantly upregulated. Kyoto Encyclopedia of Genes and Genomes analysis of signaling pathways of osteogenic target genes revealed that genes of the BMP, Wnt, and extracellular matrix-receptor interaction signaling pathways were enriched (Figure 2E).

β-Ecdysterone Induced the Expression of BMP-2, Runx2, and Osterix mRNA in MC3T3-E1 Cells In Vitro
BMP-2 has been shown to induce osteoblast differentiation rapidly and effectively in vitro. Furthermore, BMP-2 plays a vital role in bone formation and remodeling. Using mRNA sequencing analysis, our study found that β-ecdysterone enhanced the enrichment of genes from the osteogenic signaling pathway, including the BMP signaling pathway. To investigate the effect of genes of the BMP-2 signaling pathway on β-ecdysterone-mediated (0/150 μM) osteogenic differentiation of MC3T3-E1 cells, we performed RT-qPCR to measure the expression of osteogenic-related genes. The RT-qPCR results showed that β-ecdysterone significantly increased the expression of BMP-2, Runx2, Col I, and Osterix (Figure 3A). To further verify the involvement of BMP-2 in β-ecdysterone induced osteogenic differentiation, we used the BMP-2 receptor antagonist noggin to block BMP-2 signaling in MC3T3-E1 cells. Noggin treatment of MC3T3-E1 cells reduced the
expression of BMP-2, Runx2, Osterix, and Collagen I mRNA. These data suggested that the BMP-2 signaling pathway plays a significant role in osteogenic differentiation of MC3T3-E1 cells mediated by β-ecdysterone (Figure 3A).

### β-Ecdysterone Regulated Osteogenic Differentiation of MC3T3-E1 Cells Through the BMP-2/Smad/Runx2/Osterix Signaling Pathway

Western blotting was used to detect the expression of the BMP-2, Smad1/5, phosphorylated (p)-Smad1/5, RUNX2, and osterix proteins induced by β-ecdysterone. We confirmed the role of the BMP-2/SMAD/RUNX2/Osterix pathway in β-ecdysterone-mediated osteogenic differentiation of MC3T3-E1 cells. Our data showed that β-ecdysterone significantly increased intracellular BMP-2, Smad1/5, p-Smad1/5, Runx2, and osterix proteins; the ratio of protein to phos-protein also increased significantly, with the most significant increase observed at 150 μM (Figure 4). Furthermore, there was no effect on the levels of the GAPDH protein. The protein expression of BMP-2, Smad1/5, phosphorylated (p)-Smad1/5, Runx2, and Osterix were significantly decreased in MC3T3-E1 cells treated with noggin. Therefore, these data suggested that the BMP-2/Smad/Runx2/Osterix signaling pathway is involved in the regulation of osteogenic differentiation of MC3T3-E1 cells by β-ecdysterone.

Immunofluorescence was used to detect the expression of collagen I in the cytoplasmic region and the effect induced by exposure to noggin. The results showed that collagen I expression was most significant in the experimental group when the concentration of β-ecdysterone was 150 μM. In contrast, collagen I expression...
in cells treated with noggin was generally decreased ($p < 0.05$), as shown in Figures 3B,C. These data suggest that noggin may inhibit the positive regulation of collagen I expression in MC3T3-E1 cells.

**Therapeutic Effect of β-Ecdysterone on Femoral Bone Defects in Rats**

The bone defect model was established in this study by drilling the femoral condyle in rats. According to the results of the in vitro experiment, the rats were divided into three groups: the control group (0 mg/kg of β-ecdysterone was injected intraperitoneally), experimental group (72 mg/kg of β-ecdysterone was injected intraperitoneally), and the sham operation group. Rats were injected intraperitoneally with the corresponding drugs every 3 days after surgery and were sacrificed at the eighth week for micro-CT scanning, reconstruction, and immunohistochemical staining.

Table 4 and Figure 5 show the results of weight and histopathology analysis of different tissues in the control, sham, and experimental groups. Tissue sections of the liver and kidney of rats treated with 72 mg/kg of β-ecdysterone for 4 weeks showed no signs of abnormality and toxicity, respectively. This further confirmed that β-ecdysterone did not exert any undesirable toxic effects on the animals at low doses.

As shown in Figure 6, micro-CT was used to evaluate changes in the femoral condylar defect in rats. On micro-CT reconstruction analysis, the images clearly showed characteristics of changes in the bone regeneration process.
Compared to the control/PBS group, more new bone tissue had regenerated in the experimental group (Figure 6). On quantitative analysis, the volume and density of new bone tissue increased in the experimental group at 4 and 8 weeks (p < 0.05); however, there was no significant difference between the sham and experimental groups (p > 0.05) at 8 weeks. In addition to micro-CT, HE staining was used to detect histological changes in newly formed bone tissue. Unlike in the control group, the calcium phosphorus crystals in the bone tissue of the experimental group were arranged in a regular shape and the collagenous fibers were arranged in a circular shape. The direction of arrangement of the collagenous fibers was consistent with that of the bone cavities; this is a typical histomorphological characteristic of newly formed bone. Immunohistochemistry was used to detect the protein expression levels of BMP2, Smad4, Runx2, and Osterix. Compared to the control group, the expression of target protein in the experimental group was significantly increased. In addition, there was no significant difference in expression between the sham and control groups at 4 and 8 weeks (Figure 7).

**DISCUSSION**

Fractures, traumatic bone defects, and osteoporosis are increasingly prominent and common diseases worldwide, and adequate bone regeneration is the key to their successful treatment. To our knowledge, bone regeneration is a common process of intramembranous ossification and endochondral ossification, initiated by periosteal bone progenitor cells, which first form avascular cartilage tissue and is then replaced by bone tissue (Slade and Chou 1998). BMSCs play an essential role in bone repair (Wang et al., 2013). Among the cytokines involved in bone formation, the transcription factor BMP2 is the most studied, but its induction mechanism in bone progenitor cells is poorly understood. This study showed that β-ecdysterone promotes bone formation and improves cell proliferation and differentiation by activating the BMP2/Smad/Runx2/Osterix signaling pathway, suggesting that β-ecdysterone can effectively improve bone volume and quality. Mechanistically, BMP2 binds to the BMPR-II receptor on the cell membrane and activates the BMPR-II receptor and BMPR-I receptor, regulates the binding of the downstream transcription factor Smad1/5/8 to the transcription factor Smad4, which is transferred to the nucleus and activates the downstream nuclear transcription factor Runx2. Runx2 further enhances Osterix fragment transcription and translation in the nucleic acid chain, promoting osteogenic proteins, extracellular matrix deposition, and calcium mineralization, leading to fracture regeneration. In general, our study suggests that β-ecdysterone is a positive regulator of bone regeneration, promoting BMSC proliferation and osteogenic differentiation.

**TABLE 4** | The weight of rats in different groups (0 and 4 weeks after surgery; n = 5).

| Time (days) | PBS group       | Sham group      | β-ecdysterone group | Statistics (F, p) |
|-------------|-----------------|-----------------|---------------------|-------------------|
| 0 weeks     | 204.7 ± 2.48    | 204.4 ± 2.96    | 203.9 ± 2.76        | F = 0.13, p = 0.89 |
| 4 weeks     | 306.9 ± 4.86    | 308.5 ± 3.59    | 311.0 ± 4.87        | F = 1.66, p = 0.23 |
| Statistics (t, p) | t = 33.6, p < 0.01 | t = 35.9, p < 0.01 | t = 39.8, p < 0.01 |

Values are expressed by means X ± SD (n = 5). **p < 0.01, ***p < 0.001, NS, no significance.
β-ecdysterone has been shown to effectively protect mouse osteoblasts from glucocorticoid-induced apoptosis and autophagy (Tang et al., 2018a). It also blocks IL-1β-induced chondrocyte apoptosis and the inflammatory response by inhibiting NF-κB signaling (Zhang et al., 2014). In their in vitro study, Jian et al. (2013) demonstrated that β-ecdysterone can induce BMP-2 dependent osteogenic differentiation and proliferation of human periodontal ligament stem cells through the extracellular signal-regulated kinase pathway. However, the results only evaluated the toxicity of β-ecdysterone and did not determine whether it promoted osteogenic differentiation of BMSCs. Data regarding the connection between estrogen receptors and BMP signaling are lacking. Studies have shown that cytokine sensitivity screening considers the BMP4 signaling pathway to be crucial for treating ER + breast cancer (Shee et al., 2019). In addition, dehydrodiconiferyl alcohol has been found to promote BMP-2-induced osteoblastogenesis through its agonistic effects on estrogen receptors (Lee et al., 2018). In their study, Pang et al. found that quercetin stimulates BMSC differentiation through an estrogen receptor-mediated pathway (Pang et al., 2018). We therefore suspect the presence of an interaction between BMP signaling and estrogen receptors; β-ecdysterone may have promoted osteogenic differentiation of BMSCs in our study by activating estrogen receptors in vivo.

Considering the importance of BMSCs in bone repair and reconstruction, we investigated the effects of β-ecdysterone on BMSCs in vitro and in vivo. In vitro, we used the MC3T3-E1 cell line, which includes osteogenic precursor cells cloned from the skull of C57BL/6 mice, to replace BMSC cells. Repeated
subculture of this cell line has been reported to maintain the phenotype of high ALP activity of osteoblasts; it also promotes differentiation into osteoblasts and osteocytes in vitro, forming calcified bone tissue and mineral deposits of hydroxyapatite (Kunimatsu et al., 2018). This cell line has proven to be a viable model for exploring osteoblast proliferation, maturation, and differentiation (Gal et al., 2000) and is commonly used to study the effects of drugs on osteoblasts.

In vitro cell proliferation experiments showed that β-ecdysterone promoted MC3T3-E1 cell proliferation at 25–200 mM. In contrast, MC3T3-E1 cell proliferation and metabolism were inhibited after 7 days of culture or when the concentration was greater than 400 mM. Microscopically, cells reached fusion after 7 days of culture; this may explain why the effect of β-ecdysterone on the proliferation of MC3T3-E1 cells was limited to the early stage of cell culture. Our results also indicate that higher levels of β-ecdysterone exert a specific toxic effect on MC3T3-E1 cells. In vivo experiments were performed using 0 and 150 μM of β-ecdysterone (72 mg/kg), which was injected intraperitoneally in femoral condylar defect model rats. The results showed that the bone defect regenerated to different degrees after 8 weeks and the effect was most significant at 72 mg/kg. This result demonstrates that β-ecdysterone can promote osteoblast proliferation in vivo and has obvious biosafety. In previous in-vivo and in-vitro studies, the effect of β-ecdysterone on cell proliferation was complex (Tang et al., 2018b). In our study, β-ecdysterone at an appropriate concentration showed the ability to promote bone progenitor cell proliferation, which is essential for bone tissue regeneration; this is because the body needs enough bone cells to rebuild after fracture, and the number of cells that can be transplanted by autologous or allograft is limited.

Bone formation is a complex process. In addition to cell proliferation, deposition and mineralization of the extracellular matrix are also important (Jia et al., 2003). Therefore, ideal methods for bone regeneration must promote bone progenitor
cell proliferation and stimulate osteogenic differentiation. In this study, MC3T3-E1 cells were cultured with different concentrations of β-ecdysterone to further verify the effect of β-ecdysterone on osteoprogenitor cell differentiation. The final data showed that β-ecdysterone significantly increased ALP activity in MC3T3-E1 cells, and the increase was more pronounced at a concentration of 200 mM Runx2 is an early phenotypic marker of mature osteoblasts similar to ALP, while COL-1 and OPN are late phenotypic markers of osteoblast differentiation (Zhang et al., 2010; Zhou et al., 2014). We demonstrated that β-ecdysterone induced significantly higher expression of the COL-1, OPN, and Runx2 gene or protein in MC3T3-E1 cells than in nonstimulated controls. These results suggest that β-ecdysterone stimulates early and late differentiation of bone progenitor cells.

For the in-vivo experiments, we selected a rat partial femoral condyle defect model. In the partial defect model, a defect is usually drilled into the side of the bone to create an area of injury. Drilling through the cortical bone may extend to the underlying cancellous bone or marrow cavity. In this model, only one bone is usually injured; notably, certain cortical bone defects are simple to operate and can simulate the steps of stable fracture healing (McGovern et al., 2018). They offer many advantages over other closed and open fractures, including reduced morbidity in animals and better histomorphometric analysis. Micro-CT values and immunohistochemical staining results of the rat bone defect model showed greater new bone formation (based on mineralization measurement) in the group treated with β-ecdysterone than in the control/PBS group. In conjunction, these results suggest that β-ecdysterone stimulates osteogenic differentiation of bone progenitors at different stages in vitro and in vivo.

BMPs play a vital role in the osteogenic differentiation of different cell lines (Urist and Strates 2009; Long 2011). Through gene sequencing and differential expression analysis of osteogenic related genes in different treatment groups of MC3T3-E1 cells, we found that the genes detected in different groups of cells had significant differences in signal pathway enrichment and cell function. The BMP signaling pathway genes were ranked among the top 20 and the differences were statistically significant. BMP-2 has been reported to be a crucial regulatory factor in the BMP pathway, which can enhance the osteogenic differentiation of human BMSCs (Peng et al., 2003). Therefore, our analysis of the results of gene sequencing suggested that β-ecdysterone-enhanced osteogenic differentiation of bone progenitor cells was closely related to the BMP2 signaling pathway. Similarly, we found that β-ecdysterone upregulates BMP-2 expression at mRNA and protein levels, and the BMP-2 signaling pathway inhibitor noggin can counteract this effect in vitro. Although noggin has been observed to be nonspecific for BMP-2 (Secondini et al., 2011), genetic tests showed that β-ecdysterone did not significantly increase BMP signaling in MC3T3-E1 cells. These results suggest that the BMP-2 signaling pathway plays an essential role in β-ecdysterone-induced osteogenic differentiation of bone progenitor cells.

Regarding the induction mechanism of BMP-2, many studies have shown that it is related to the MAPK signaling pathway (Park et al., 2019). Previous studies have reported that the ERK pathway is involved in the differentiation of periodontal ligament cells and osteoblasts (Tóth et al., 2008), but our results suggest that the increased expression of BMP-2 and other osteogenic proteins and genes is directly related to the BMP2/Smad/Runx2/Osterix pathway. The noggin inhibitor can abrogate this effect. According to our data and previous studies (Qiao et al., 2005; Wang et al., 2012; Fischerauer et al., 2013), we speculate that the mechanism of action involves BMP-2 active the BMP type 2 receptor, but it interacts and activates the BMP type 1 receptor which then the BMP type 1 receptor activates downstream signaling pathways, by phosphorylation of Smad1, Smad5, or Smad8. Smad1/5/8 activates and binds to Smad4 and enters the cell nucleus to regulate the transcription function of specific genes. The Smad protein, as a coregulatory, interacts with Runx2 to participate in osteoblast phenotypic gene expression and differentiation (Phimphila et al., 2006). In addition, Runx2 can interact with osteoblast specifics acting element 2 in the osteocalcin promoter region to stimulate osteocalcin expression. There are osteoblast specifics acting element 2-like elements in the promoter regions of osteoblast-related genes such as type I collagen, osteocalcin, and osteopontin, and Runx2 can bind to these osteoblast specifics acting element 2-like elements to activate gene expression (Liu and Lee 2013); however, this mechanism requires further study.

In summary, β-ecdysterone can be used as a safe and effective agent for bone regeneration to resolve insufficient bone regeneration and severe osteoporosis caused by decreased osteogenic capacity. Thus, β-ecdysterone has excellent research value and application prospects. Furthermore, it remains to be explored whether β-ecdysterone can be incorporated into bone regeneration biomaterials to promote bone tissue regeneration for the treatment of critical bone defects in the future.

CONCLUSION

This study is the first to demonstrate that β-ecdysterone has good biosafety in mammals in vitro and in vivo and can promote proliferation and induce osteogenic differentiation of bone progenitors through the BMP2/Smad/Runx2/Osterix signaling pathway. This indicates its considerable potential as a therapeutic agent for bone regeneration and repair.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

ETHICS STATEMENT

The animal study was reviewed and approved by The Research Ethics Committee of the Affiliated Hospital of the North Sichuan Medical College (2021–26).
AUTHOR CONTRIBUTIONS

C-PY and X-KW: Methodology, Resources, Investigation, Writing-original manuscript. KJ: Supervision, Writing-review and editing. CY: Investigation. CX, YW, and CP: Investigation, Resources. IC: Supervision, Validation. Y-LL: Conceptualization, Supervision, Writing-reviewing and editing.

FUNDING

This work was supported by the National Science Foundation of China (Grant Nos. 82102578 and 82102571), Applied Basic Research Programs of the Science and Technology Department of Sichuan Province (2021YJ0467), Research Project of the Affiliated Hospital of North Sichuan Medical College (2021ZK001), and the Research Project of the North Sichuan Medical College (CBY20-QA-Z04).

REFERENCES

Abdallah, B. M., Haack-Sorensen, M., Burns, J. S., Elsabab, N., Jakob, F., Hokland, P., et al. (2005). Maintenance of Differentiation Potential of Human Bone Marrow Mesenchymal Stem Cells Immortalized by Human Telomerase Reverse Transcriptase Gene Despite of Extensive Proliferation. Biochem. biophy. Res. Commun. 326, 527–538. doi:10.1016/j.bbrc.2004.11.059

Abiramasundari, G., Mohan Gowda, C. M., and Sreepriya, M. (2018). Selective β-Ecdysone in Tinospora Cordifolia on Osteoblast Cells. J. Ayurveda Integr. Med. 9, 161–168. doi:10.1016/j.jaim.2017.04.003

Cai, H., Zou, J., Wang, W., and Yang, A. (2021). BMP2 Induces hMSC Osteogenesis and Matrix Remodeling. Mol. Med. Rep. 23, 11764. doi:10.3892/mmr.2020.11764

Catalán, R. E., Martínez, A. M., Aragones, M. D., Miguel, B. G., Robles, A., and Godoy, J. E. (1985). Alterations in Rat Lipid Metabolism Following Ecdysterone Treatment. Comp. Biochem. physiology. B, Comp. Biochem. 81, 771

Chen, Z., Wang, X., Shao, Y., Shi, D., Chen, T., Cui, D., et al. (2011). Synthetic Osteogenic Growth Peptide Promotes Differentiation of Human Bone Marrow Mesenchymal Stem Cells to Osteoblasts via RhoA/ROCK Pathway. J. Cell Biochem. 358, 221–227. doi:10.1002/jcb.20311

Clark, D. P., and Badea, C. T. (2021). Advances in Micro-CT Imaging of Small Animals. Phys. Medica 88, 175–192. doi:10.1016/j.ejmp.2021.07.005

da Silva Meirelles, L., Fontes, A. M., Covas, D. T., and Caplan, A. I. (2009). Mechanisms Involved in the Therapeutic Properties of Mesenchymal Stem Cells. Cytokine & growth factor Rev. 20, 419–427. doi:10.1016/j.cytogfr.2009.11.002

Dai, W.-W., Wang, L.-B., Jin, G.-Q., Wu, H.-J., Zhang, J., Wang, C.-L., et al. (2017). Beta-Ecdysone Protects Mouse Osteoblasts from Glucocorticoid-Induced Apoptosis In Vitro. Ped. Blood. 83, 888–894. doi:10.1007/s10043-017-0808

Feng, C., Xiao, L., Yu, C. J., Li, D. Y., Tang, T. Y., Liao, W., et al. (2020). Simvastatin Regulates BMP-6 and BMPR-1a Are Up-Regulated in the Growth Plate of the Fractured Tibia. J. Orthop. Res., 31, 357–363. doi:10.1002/jor.22238

Gal, T. J., Munoz-Antonio, T., Muro-Cacho, C. A., and Llovet, D. W. (2000). Radiation Effects on Osteoblasts In Vitro: A Potential Role in Osteoradionecrosis. Arch. Otolaryngol. Head. Neck Surg. 126, 1124–1128. doi:10.1001/archotol.126.9.1124

Gao, L., Cai, G., and Shi, X. (2008). BETA-Ecdysterone Induces Osteogenic Differentiation in Mouse Mesenchymal Stem Cells and Relieves Osteoporosis. Biol. Pharm. Bull. 31, 2245–2249. doi:10.1248/bpb.31.2245

Hak, D. J., Fitzpatrick, D., Bishop, J. A., Marsh, J. L., and Hoff, S., Schnettler, R., et al. (2014). Delayed Union and Nonunions: Epidemiology, Clinical Issues, and Financial Aspects. Injury 45 (Suppl. 2), S3–S7. doi:10.1016/j.injury.2014.04.002

Jia, T.-L., Wang, H.-Z., Xie, L.-P., Wang, X.-Y., and Zhang, R.-Q. (2003). Daidzein Enhances Osteoblast Growth That May Be Mediated by Increased Bone Morphogenetic Protein (BMP) Production. Biochem. Pharmacol. 65, 709–715. doi:10.1016/0006-2952(02)01585-x

Jian, C.-X., Liu, X.-F., Hu, J., Li, C.-J., Zhang, G., Li, Y., et al. (2013). 20-Hydroxyecdysone-induced Bone Morphogenetic Protein-2-dependent Osteogenic Differentiation through the ERK Pathway in Human Periodontal Ligament Stem Cells. Eur. J. Pharmacol. 698, 48–56. doi:10.1016/j.ejphar.2012.04.044

Ko, E. C., and Sumner, D. R. (2021). How Faithfully Does Intramembranous Bone Regeneration Recapitulate Embryonic Skeletal Development? Dev. Dyn. 250, 377–392. doi:10.1002/dvdy.240

Kunimatsu, R., Gunji, H., Tsuka, Y., Yoshimi, Y., Awada, T., Sumi, K., et al. (2018). Effects of High-Frequency Near-Infrared Diode Laser Irradiation on the Proliferation and Migration of Mouse Calvarial Osteoblasts. Lasers Med. Sci. 33, 959–966. doi:10.1007/s11013-017-2426-0

Lee, W., Ko, K. R., Kim, H.-K., Lim, S., and Kim, S. (2018). Dehydrodiconiferyl Alcohol Promotes BMP-2-Induced Osteoblastogenesis through its Agonistic Effects on Estrogen Receptor. Biochem. biophy. Res. Commun. 495, 2242–2248. doi:10.1016/j.bbrc.2017.12.079

Li, Z., and Helms, J. A. (2021). Drill Hole Models to Investigate Bone Repair. Methods Mol. Biol. Clift. N.J.) 2221, 193–204. doi:10.1007/978-1-0716-0989-7_12

Lin, Z.-Y., Duan, Z.-X., Guo, X.-D., Li, J.-F., Lu, H.-W., Zheng, Q.-X., et al. (2010). Bone Induction by Biometric PLGA-(PEG-ASP)n Copolymer Loaded with a Novel Synthetic BMP-2-Related Peptide In Vitro and In Vivo. J. Control. Release 144, 190–195. doi:10.1016/j.jconrel.2010.02.016

Liu, Q., Zhang, X., Jiao, Y., Liu, X., Wang, Y., Li, S. L., et al. (2018). In Vitro cell Behaviors of Bone Mesenchymal Stem Cells Derived from Normal and Postmenopausal Osteoporotic Rats. Int. J. Mol. Med. 41, 669–678. doi:10.3892/imj.2017.3280

Liu, T. M., and Lee, E. H. (2013). Transcriptional Regulatory Cascades in Runx2-dependent Bone Development. Tissue Eng. Part B Rev. 19, 254–263. doi:10.1089/ten.teb.2012.0527

Long, F. (2011). Building Strong Bones: Molecular Regulation of the Osteoblast Lineage. Nat. Rev. Mol. Cell Biol. 13, 27–38. doi:10.1038/nrm3254

McGovern, J. A., Griffin, M., and Hutmacher, D. W. (2018). Animal Models for Bone Tissue Engineering and Modelling Disease. Dis. Model. Mech. 11. doi:10.1242/dmm.033084

Miyazono, K., Kamiya, Y., and Morikawa, M. (2010). Bone Morphogenetic Protein Receptors and Signal Transduction. J. Biochem. 147, 35–51. doi:10.1093/jb/mvp148

Pang, X. G., Cong, Y., Bao, N. R., Li, Y. G., and Zhao, J. N. (2018). Quercetin Stimulates Bone Marrow Mesenchymal Stem Cell Differentiation through an Estrogen Receptor-Mediated Pathway. Biomed. Res. Int. 2018, 4178021. doi:10.1155/2018/4178021

Park, M., Choi, H. K., and An, J. H. (2019). Taurine Activates BMP-2/Wnt3a-Mediated Osteoblast Differentiation and Mineralization via Akt and MAPK Signaling. Iran. J. Public Health 48, 1960

Peng, Y., Kang, Q., Cheng, H., Li, X., Sun, M. H., Jiang, W., et al. (2003). Transcriptional Characterization of Bone Morphogenetic Proteins (BMPs)-Mediated Osteogenic Signaling. J. Cell. Biochem. 90, 1149–1165. doi:10.1002/jcb.10744

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fcell.2022.883228/full#supplementary-material
